HDFC Mutual Fund Launches Fifth Edition of Cancer Cure Fund
New Delhi, November 17, 2026: HDFC Asset Management Company Limited (HDFC AMC), investment manager to HDFC Mutual Fund, has announced the fifth edition of its Cancer Cure series with the launch of the HDFC Charity Fund for Cancer Cure (Feb 2030), in collaboration with the Indian Cancer Society (ICS). The initiative aims to support the treatment of underprivileged cancer patients through contributions from investors.
The New Fund Offer (NFO) opened on November 16, 2026, and will close on November 30, 2026. The scheme is a Fixed Maturity Plan with a tenure of 1,169 days. Investors can contribute towards the cause by opting to donate 50% or 75% of the distribution income earned through the Income Distribution cum Capital Withdrawal (IDCW) option to ICS. HDFC AMC will match the contributions, subject to a limit of ₹16 crore per financial year. The investment amount will be returned to investors upon maturity.
HDFC AMC has also waived the investment management and advisory fee for the scheme, with the stated aim of ensuring that a greater share of the proceeds can support cancer treatment.
Launched in 2011 as India's first cancer fund, the Cancer Cure series has raised ₹292.41 crore for ICS, including direct contributions from HDFC AMC, as of September 2026. Of this amount, ₹273.28 crore had been disbursed towards the treatment of 17,435 patients across 22 hospitals as of August 31, 2026. Nearly one in four patients supported through the initiative was a child aged 15 or below.
According to ICMR-NCDIR, India recorded an estimated 14,61,427 new cancer cases in 2022, with a new diagnosis occurring approximately every 22 seconds. The financial burden of treatment continues to pose a challenge for many families seeking timely medical care.
Commenting on the announcement, Mr. Navneet Munot, Managing Director and Chief Executive Officer, HDFC Asset Management Company Limited, said, “At HDFC AMC, we believe that the true measure of an institution's success lies not just in the value it creates, but also in the difference it makes to people's lives. Over the years, the Cancer Cure initiative has brought together investors, the industry and a committed partner like the Indian Cancer Society to address a cause that affects countless families. The ₹292 crore contribution and the thousands of patients who have received support are a testament to what sustained collective effort can achieve. We hope this fifth edition will build on that legacy and inspire more people to become part of a cause where every contribution can make a meaningful difference.”
Ms. Usha Thorat, Indian Cancer Society, added, “For a family facing cancer, access to timely treatment can make all the difference. However, the cost of care often puts treatment beyond the reach of those who need it most. The support received through HDFC Mutual Fund's Cancer Cure series has enabled us to extend financial assistance to over 17,000 patients across 22 hospitals. Beyond the financial support, this initiative has helped bring hope to families at an extremely difficult time. We are grateful for this continued partnership and look forward to reaching many more patients through its fifth edition.”
Investors seeking further information about the scheme can visit the HDFC Charity Fund for Cancer Cure (Feb 2030) page and refer to the Scheme Information Document before investing.

